Invokamet is a New Type 2 Diabetes Treatment
August 8, 2014 – The Food and Drug Administration approved Invokamet (canagliflozin/metformin), a new combination product for use in the treatment of adults with Type 2 Diabetes. Invokament is manufactured by Janssen Pharmaceuticals.
As a combination product Invokamet includes Canagliflozin which helps decrease the reabsorption in the kidneys and Metformin which primarily reduces the glucose production in the liver but also decreases glucose absorption from the intestines and increases the utilization of glucose by body cells and the body’s response to glucose. Invokamet will be available in 50mg/500mg, 50mg/1,000mg 150mg/500mg and 150/1,000mg strength combination tablets.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.